110 related articles for article (PubMed ID: 35587018)
21. Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Bessou A; Colin X; De Nascimento J; Sopwith W; Ferrante S; Gorsh B; Gutierrez B; Sansbury L; Willson J; Sapra S; Paka P; Wang F
Eur J Health Econ; 2023 Apr; 24(3):321-333. PubMed ID: 35610398
[TBL] [Abstract][Full Text] [Related]
22. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data.
Chaudhary MA; Holmberg C; Lakhdari K; Smare C; Theriou C; Dale P; Penrod JR
J Med Econ; 2021; 24(1):607-619. PubMed ID: 33870833
[TBL] [Abstract][Full Text] [Related]
24. Do systemic treatments delivered after Nivolumab result in better outcomes? A bicentric case-control study.
Darrason M; Chatelain E; Ranchon F; Gervaise C; Duruisseaux M; Couraud S
Respir Med Res; 2020 Mar; 77():100-105. PubMed ID: 32512522
[TBL] [Abstract][Full Text] [Related]
25. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice.
Merino Almazán M; Duarte Pérez JM; Marín Pozo JF; Ortega Granados AL; Muros De Fuentes B; Quesada Sanz P; Gago Sánchez AI; Rodríguez Gómez P; Jurado García JM; Artime Rodríguez-Hermida F; Martínez Bautista MJ; Rueda Ramos A; Mora Rodríguez B; Martínez Díaz MC; Nieto Guindo P; Garrido Siles M; Villatoro Roldán R; Roldán Morales JC; Artacho Criado SM; Baños Roldán Ú; Inoriza Rueda Á; Garrido Martínez MT
Int J Clin Pharm; 2019 Feb; 41(1):272-279. PubMed ID: 30578473
[TBL] [Abstract][Full Text] [Related]
26. Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Geier M; Descourt R; Corre R; Léveiller G; Lamy R; Goarant É; Bizec JL; Bernier C; Quéré G; Amrane K; Gaye E; Lucia F; Burte E; Chouaid C; Robinet G
Cancer Med; 2020 Oct; 9(19):6923-6932. PubMed ID: 32412157
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
28. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.
Gao L; Li SC
Appl Health Econ Health Policy; 2019 Jun; 17(3):371-380. PubMed ID: 30535675
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
[TBL] [Abstract][Full Text] [Related]
30. Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Hu S; Tang Z; Harrison JP; Hertel N; Penrod JR; May JR; Juarez-Garcia A; Holdgate O
Pharmacoecon Open; 2023 Mar; 7(2):273-284. PubMed ID: 36897427
[TBL] [Abstract][Full Text] [Related]
31. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
Roth JA; Yuan Y; Othus M; Danese M; Wagner S; Penrod JR; Ramsey SD
J Med Econ; 2021; 24(1):79-86. PubMed ID: 33334176
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Smare C; Dave K; Juarez-Garcia A; Abraham P; Penrod JR; Camidge DR; Yuan Y
J Med Econ; 2021; 24(1):1124-1133. PubMed ID: 34465261
[TBL] [Abstract][Full Text] [Related]
33. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
34. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
35. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
[TBL] [Abstract][Full Text] [Related]
36. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
[TBL] [Abstract][Full Text] [Related]
37. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
[TBL] [Abstract][Full Text] [Related]
38. Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States.
Thach A; Jones E; Pappert E; Pike J; Wright J; Gillespie A
J Med Econ; 2021; 24(1):540-549. PubMed ID: 33819121
[TBL] [Abstract][Full Text] [Related]
39. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
40. Health care resource utilization and treatment variability in the care of patients with advanced or metastatic colorectal or gastric cancer.
Hess LM; Zhu YE; Fang Y; Liepa AM
J Med Econ; 2021; 24(1):930-938. PubMed ID: 34289799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
